PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33850004-11	2021	This study demonstrates that idasanutlin can overcome resistance to the BCL-2 inhibitor venetoclax in preclinical neuroblastoma model systems, which supports clinical development of a treatment strategy combining the two therapies.	RG7388	29-40	BCL2 apoptosis regulator	Homo sapiens	72-77	
29768700-1	2018	Venetoclax (ABT-199) and idasanutlin (RG7388) are efficient anticancer drugs targeting two essential apoptosis markers, Bcl-2 and MDM2, respectively.	RG7388	25-36	BCL2 apoptosis regulator	Homo sapiens	120-125	
32827690-12	2020	This study further opens new avenues for the use of RG-7388 in treating osteosarcomas that often becomes resistant to chemotherapy due to Bcl-2 overexpression.	RG7388	52-59	BCL2 apoptosis regulator	Homo sapiens	138-143